An interventional study of Transcutaneous electrical stimulation (Elitone) in Stress Urinary Incontinence, sponsored by Elidah, Inc.. Completed at 1 site in United States. Open to female participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-13.
Sponsored by Elidah, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 190 studies in Urinary Incontinence, Stress with a site in United States — 28 open to participants now, 41 under way, 4 of them phase 3. Urinary Incontinence, Stress · United States.
Among the 190 studies in Urinary Incontinence, Stress with a site in United States, this one is the 90th largest by enrollment of the 164 interventional ones that give a count, is one of 10 that started in 2018, is one of 109 with no phase, and was the 108th registered.
655 studies on the registry are indexed under Urinary Incontinence, Stress; 123 are open to participants now.
Browse Urinary Incontinence, Stress studies →28 of the 190 studies in Urinary Incontinence, Stress with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada
Ages 18+ · Women only
University of Miami · Sites in United States
Ages 18+ · Women only
Mayo Clinic · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Eli Lilly and Company · Sites in United States, Canada, China and 6 more countries
Ages 18+ · Women only
Ohio State University · Sites in United States
Ages 18–50 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 76 Urinary Incontinence, Stress studies recruiting now, 43 (57%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.
This study: 21 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
190 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 18 · Phase 3 24 · Phase 4 15
First in 2001; this study’s year is marked. 10 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is above the median of 68 across 510 interventional studies indexed under Urinary Incontinence, Stress.
Median enrollment 99 across the 164 interventional studies, 98 across the 26 observational. Of the 129 that completed or were terminated, 56 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 190 have an industry lead sponsor. The 10 most frequent:
Elidah, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Elidah, Inc. has 2 studies filed under Urinary Incontinence, Stress — fewer than ten, so there is no comparison to draw.
9 of the studies in Urinary Incontinence, Stress with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06968741UroMems SASA Study to Assess the Safety and Effectiveness of the UrOActive® Artificial Urinary sPHincter (AUS) | 2026-12 |
| NCT06111209Brigham and Women's HospitalThe Anabolic Effect of Testosterone on Pelvic Floor Muscles | 2026-12-31 |
| NCT06369922University of RochesterTENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence. | 2027-01-31 |
| NCT06706362Ohio State UniversityAssessing the Utility of Prophylactic Antibiotics at Time of Urethral Bulking Using Bulkamid (Bulkamid Study) | 2027-04-15 |
| NCT07008898University of Alabama at BirminghamSequence of Midurethral Sling Placement During Robotic Sacrocolpopexy | 2027-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 190 studies in Urinary Incontinence, Stress with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized controlled study in which subjects are assigned to either a treatment group or a control (sham) group. Pre- and post-study outcome measures evaluate the change in incontinence episodes on women with mild-moderate stress urinary incontinence.
The Elitone device delivers electrical muscle stimulation to pelvic floor muscles through a disposable surface electrode shaped to fit the perineal region. In typical use women self-administer treatment 20 minutes per day, 5x per week, for 6-12 weeks. Elidah is initiating a prospective, randomized clinical study to demonstrate device efficacy. The study expands a similar pilot to 60 subjects, adds a control arm (sham device) and includes additional outcome measures. Like the earlier study, subjects will self-administer treatment over multiple weeks while maintaining daily logs of their treatment and incontinence symptoms. This is a home-use study, which does not require clinic visits. Accordingly, this allows subject recruitment from across US.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Predominant Mild-moderate stress incontinence symptoms as determined by self-reported typical number of accidents of 1 per 24 hours or more.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Elitone Surface electrical stimulation with a treatment waveform (medium frequency modulated at 50Hz)
Device: Transcutaneous electrical stimulation (Elitone)
Elitone Sham surface electrical stimulation at a very low frequency not known to contract muscles.
Device: Transcutaneous electrical stimulation (Elitone)
Transcutaneous perineal area electrical stimulation
Also known as: Elitone
Efficacy Assessed by Percent Reduction in Urinary Incontinence Episodes
The percent reduction in average number of urinary incontinence episodes over 12 weeks.
Time frame: 12 weeks
Efficacy Assessed by Percent Reduction in Average Pad Weight
The percent reduction of pad weight in a day over the 12 weeks.
Time frame: 12 weeks
Efficacy Assessed by Change in Incontinence Quality of Life Questionnaire (I-QOL)
The efficacy assessed by change in Incontinence quality of life questionnaire (I-QOL). It comprises 22 questions, to which the subject provides a numeric response on a 1-5 scale. 1 = not at all , 2 = a little, 3 = moderately, 4 = quite a bit and 5 = extremely. The score is the sum of the numeric responses, which can range from 22 to 110. The lower the value the less times it happens and the better outcome.
Time frame: 12 weeks
Pads Per Day
Reduction of number of pads used per day
Time frame: 12 weeks
| Milestone | Treatment | Control |
|---|---|---|
| Started | 57 | 30 |
| Completed | 40 | 18 |
| Not completed | 17 | 12 |
| Withdrew: Lost to follow-up | 11 | 7 |
| Withdrew: Withdrawal by subject | 6 | 5 |
| Milestone | Treatment | Control |
|---|---|---|
| Started | 40 | 18 |
| Completed | 35 | 13 |
| Not completed | 5 | 5 |
| Withdrew: Protocol violation | 5 | 5 |
The percent reduction in average number of urinary incontinence episodes over 12 weeks.
| percent reduction in leaks/day | Treatment | Control |
|---|---|---|
| Efficacy Assessed by Percent Reduction in Urinary Incontinence Episodes | 52.8 ± 36.3 | 7.9 ± 55.9 |
The percent reduction of pad weight in a day over the 12 weeks.
| percentage reduction in pad weight | Treatment | Control |
|---|---|---|
| Efficacy Assessed by Percent Reduction in Average Pad Weight | 38.3 ± 62.4 | 25.3 ± 48.8 |
The efficacy assessed by change in Incontinence quality of life questionnaire (I-QOL). It comprises 22 questions, to which the subject provides a numeric response on a 1-5 scale. 1 = not at all , 2 = a little, 3 = moderately, 4 = quite a bit and 5 = extremely. The score is the sum of the numeric responses, which can range from 22 to 110. The lower the value the less times it happens and the better outcome.
| Change of score on a scale | Treatment | Control |
|---|---|---|
| Efficacy Assessed by Change in Incontinence Quality of Life Questionnaire (I-QOL) | 20.8 ± 20.8 | 10.3 ± 21.8 |
Reduction of number of pads used per day
| percentage reduction | Treatment | Control |
|---|---|---|
| Pads Per Day | 35.0 ± 34.1 | 8.2 ± 59.9 |
Collected over Duration of the 12-week study. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment | 0/35 (0%) | 0/35 (0%) | 1/35 (2.9%) |
| Control | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
| Event | Treatment | Control |
|---|---|---|
| Transient muscle painMusculoskeletal and connective tissue disorders | 1/35 | 0/13 |
| Age, Continuous(years) | Treatment | Control | Total |
|---|---|---|---|
| Mean | 48.7 ± 13.3 | 44.7 ± 7.0 | 47.6 ± 12.0 |
| Sex: Female, Male(Participants) | Treatment | Control | Total |
|---|---|---|---|
| Female | 35 | 13 | 48 |
| Male | 0 | 0 | 0 |
| Race and Ethnicity Not Collected(Participants) | Treatment | Control | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Treatment | Control | Total |
|---|---|---|---|
| United States | 35 | 13 | 48 |
| Stress incontinence leaks/day(leaks/day) | Treatment | Control | Total |
|---|---|---|---|
| Mean | 2.81 ± 1.01 | 2.65 ± 1.17 | 2.76 ± 1.05 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2018 to primary completion in Mar 2019, 6 months.
Results were first posted in Jan 2025, 5 years 9 months after primary completion.
Of 41 industry-sponsored interventional studies with no phase under Urinary Incontinence, Stress, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 53. This study's 6 months is below that.
Counting every sponsor, half of 268 studies reached it within 19 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Urinary Incontinence, Stress →
Elidah, Inc.